ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
Sanofi India received a GST show cause notice alleging excess input tax credit claims. The total demand, including interest, is Rs. 23.74 Crore.
Sanofi Healthcare India acquired 3,500,000 equity shares (15.20%) of Sanofi India Limited via an inter-se promoter group transfer. The transaction was executed as a block deal.
Hoechst GmbH transferred 3,500,000 shares of Sanofi India Limited to Sanofi Healthcare India Private Limited. This inter-se promoter group transfer represents a 15.20% stake.
Sanofi India disclosed that the State Tax Officer, Tiruvallur dropped a ₹1.07 Crore GST demand for FY 2022-23. The company confirmed no material financial or operational impact.
Sanofi Healthcare India Private Limited, a promoter group entity, proposed an inter-se transfer of up to 3,500,000 shares from Hoechst GmbH. This transaction qualifies for open offer exemption.
The Supreme Court dismissed Sanofi India's petition to quash criminal proceedings. No penalty or operational restriction is imposed on the company at this stage.
Sanofi India Limited received a GST show cause notice regarding product classification for FY 2020-21. The total disputed demand, including tax and penalty, is ₹72.77 Crore.
Sanofi India received a GST refund of ₹1.32 Crore. The Deputy Commissioner also dropped an outstanding demand of ₹75.63 Lakh.
Sanofi India received a favorable income tax order vacating a demand of Rs. 0.73 Crore. The order drops proceedings related to non-deduction of TDS for AY 2019-20.
Sanofi India reported Q2 2026 domestic growth of 8%, driven by a 14% surge in its diabetes business. PBT (before exceptional items) grew 19% YoY to INR 112 crores.
Sanofi India Q2 2026 domestic sales grew 8% YoY, led by a 14% surge in Insulins. Profit Before Tax (PBT) rose 19% YoY to ₹1,123 Mio.
Sanofi India reported Q2'26 domestic sales growth of 8% YoY, driven by a 14% surge in its diabetes business. Management is focusing on business model transformation and operational efficiency.
Sanofi India Ltd reported revenue from operations of ₹437.7 Cr (+7.7% YoY) and net profit of ₹83.5 Cr (+20.1% YoY) for Q1 FY27.
Sanofi India’s board approved Q2 2026 unaudited financial results and reconstituted board committees. It also announced the resignation of a key managerial person.
Sanofi India Limited announced the cessation of Mr. Nakul Verma as Public Affairs & Market Access-Head. He transitions to another role within the Sanofi group effective July 31, 2026.
Mr. Rachid Ayari will resign as Whole Time Director and CFO of Sanofi India on September 30, 2026. He is transitioning to another role within Sanofi group.
Sanofi India Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing details holdings across promoter and public categories.
Sanofi India Ltd scheduled a board meeting for August 4, 2026. The meeting will consider and approve unaudited financial results for the period ending June 30, 2026.